[Present state of heparin therapy].
D001161:Arteriosclerosis / Q000188:drug therapy; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000187:drug effects; D005112:Extracorporeal Circulation; D005337:Fibrin / Q000037:antagonists & inhibitors; D005342:Fibrinolysis / Q000187:drug effects; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D006494:Heparin Antagonists; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D006967:Hypersensitivity; D009318:Natriuresis / Q000187:drug effects; D010024:Osteoporosis / Q000139:chemically induced; D011479:Protamines / Q000008:administration & dosage; D011517:Prothrombin Time; D013923:Thromboembolism / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000517:prevention & control; D013925:Thromboplastin / Q000037:antagonists & inhibitors
D006494:Heparin Antagonists; D011479:Protamines; D005337:Fibrin; D006493:Heparin; D013925:Thromboplastin
Etat actuel de l'héparinothérapie.